Epizyme, Inc.
DelistedCIK 1571498fmd_1Q1RTCHX2BAC58ZDNP4EKT6NEAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Jun 30, 2022, 43 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 8 | 10 | 22 | 24 | 16 | 37 |
| Net interest income | – | – | – | – | – | – | 5 | 7 | (5) | (22) |
| Cost of revenue | – | – | – | – | – | – | – | – | 5 | 10 |
| Gross profit | – | – | – | – | – | – | – | – | 11 | 27 |
| Research and development | 38 | 58 | 76 | 111 | 91 | 110 | 106 | 133 | 111 | 131 |
| Selling, general and administrative | – | – | – | – | – | – | 44 | 68 | 125 | 134 |
| Operating income | (1) | (3) | (55) | (133) | (112) | (137) | (128) | (177) | (225) | (238) |
| Other non-operating income (expense) | 0 | (0) | 0 | 0 | 2 | 2 | 5 | 7 | (6) | (13) |
| Income before taxes | (1) | (3) | (55) | (132) | (110) | (135) | (124) | (170) | (232) | (251) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (1) | (3) | (55) | (132) | (110) | (134) | (124) | (170) | (232) | (251) |
| Net income | (1) | (3) | (55) | (132) | (110) | (134) | (124) | (170) | (232) | (251) |
| Net income to common shareholders | (1) | (4) | (55) | (132) | – | (134) | (124) | (173) | (232) | (251) |